# MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

> **NCT07042945** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 28 (estimated)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** MK-4646

## Key facts

- **NCT ID:** NCT07042945
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2026-07-08
- **Final completion:** 2026-07-08
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07042945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07042945, "MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07042945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*